Indisulam. Eisai.

Abstract

Eisai and the EORTC are developing indisulam, a sulfonamide which inhibits progression from the G(1) phase of the cell cycle, for the potential treatment of cancer [338089]. As of January 2001, indisulam was in phase II trials in Europe for the treatment of solid tumors, and phase II US studies have been ongoing since March 2001 [400862]. In 2001, clinical development of the drug in Japan was scheduled to begin in fiscal year 2002 [396633].

• Authors: Claudiu T Supuran
• Journal: IDrugs : the investigational drugs journal (IDrugs) Vol. 5 Issue 11 Pg. 1075-9 (Nov 2002) ISSN: 1369-7056 [Print] England
• PMID: 12800061 (Publication Type: Journal Article)